Lyell Immunopharma, Inc. (LYEL)

Every figure this model derived for LYEL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 711,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 204,102,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 213,541,000 AssetsCurrent 2026-06-30
current liabilities 39,867,000 LiabilitiesCurrent 2026-06-30
equity 233,815,000 StockholdersEquity 2026-06-30
ocf -133,260,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 27,000 Revenues 2026-06-30
sbc 39,628,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up LYEL on one particular measure came for.

RatioValue
current ratio5.36
current ratio reported5.36
deferred revenue growth-100.0
dilution pct30.76
growth cv2.76
revenue growth-55.0
revenue growth per share-65.59
roic-681.96
rule of 40-950036.48

What to be careful about

What this model itself distrusts about LYEL's figures. Written by the derivation as it ran, not added afterwards.